Amoxicillin; omeprazole magnesium; rifabutin - Generic Drug Details

What are the generic sources for amoxicillin; omeprazole magnesium; rifabutin and what is the scope of patent protection?

Amoxicillin; omeprazole magnesium; rifabutin is the generic ingredient in one branded drug marketed by Talicia Holdings and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amoxicillin; omeprazole magnesium; rifabutin has thirty patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for amoxicillin; omeprazole magnesium; rifabutin

International Patents:	30
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for amoxicillin; omeprazole magnesium; rifabutin
DailyMed Link:	amoxicillin; omeprazole magnesium; rifabutin at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for amoxicillin; omeprazole magnesium; rifabutin

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

Dosage:

CAPSULE, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for amoxicillin; omeprazole magnesium; rifabutin

Drug Class	Penicillin-class Antibacterial Proton Pump Inhibitor Rifamycin Antimycobacterial
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for amoxicillin; omeprazole magnesium; rifabutin

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

J01CA	Penicillins with extended spectrum
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J04AB	Antibiotics
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS
J04	ANTIMYCOBACTERIALS
J	Antiinfectives for systemic use

US Patents and Regulatory Information for amoxicillin; omeprazole magnesium; rifabutin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes			Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes

International Patents for amoxicillin; omeprazole magnesium; rifabutin

Country	Patent Number	Title	Estimated Expiration
Japan	2016508516	ピロリ菌治療用医薬組成物
Australia	2014216373	Pharmaceutical compositions for the treatment of Helicobacter pylori
Cyprus	1122113
Hong Kong	1217645	用於治療幽門螺桿菌的藥物組合物 (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI)

Market Dynamics and Financial Trajectory for Amoxicillin, Omeprazole Magnesium, and Rifabutin

Last updated: February 17, 2026

---

What Is the Current Market Size and Growth Outlook?

Amoxicillin:
The global amoxicillin market was valued at approximately $4 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% from 2023 to 2030. The expansion is driven by increased antibiotic demand for respiratory, skin, urinary tract, and dental infections. China's rising healthcare infrastructure and outpatient prescriptions support regional growth [1].

Omeprazole Magnesium:
The proton pump inhibitor (PPI) market, with omeprazole as a leading agent, was valued at around $4.5 billion in 2022. It is expected to grow at 4% CAGR over the next seven years, propelled by the increasing prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and rising awareness of acid-related disorders. Patent expirations and biosimilar entries further influence the market dynamics [2].

Rifabutin:
The rifabutin market remains niche, primarily focused on tuberculosis (TB) and Mycobacterium avium complex (MAC) infections, especially among immunocompromised patients. The global market was valued at nearly $300 million in 2022 with a projected CAGR of approximately 2% over the next decade, driven by tuberculosis management needs in developing countries and HIV co-infection treatment programs [3].

---

How Do Patent Expirations and Generics Affect Market Trajectory?

Amoxicillin:
It is off patent globally since the early 2000s. The market now predominantly comprises generic versions, with no significant gross revenue for original manufacturers. Price competition encourages high-volume, low-margin sales, registered across numerous manufacturers.

Omeprazole Magnesium:
The original patent expired in 2001. Since then, multiple generic versions entered the market, reducing prices by over 70%. Recent biosimilar developments, or alternative formulations like delayed-release versions, shape continuing market options.

Rifabutin:
Patent exclusivity ended in the late 1990s, but limited commercial interest persists due to its niche application. The market relies mainly on generic manufacturing by multiple companies, with no major patent-driven price elevation.

---

What Are Key Drivers and Barriers?

Drivers:

• Amoxicillin: High prescription rates for bacterial infections, broad-spectrum coverage, affordability.
• Omeprazole: Growing GERD and peptic ulcer prevalence, increased awareness, generic affordability.
• Rifabutin: Rising TB cases in developing nations, increased HIV co-infection management.

Barriers:

• Amoxicillin: Resistance development reduces efficacy, leading to the need for alternative antibiotics.
• Omeprazole: Long-term use concerns, potential side effects, and entry of new PPI competitors.
• Rifabutin: Niche market, limited alternative therapies, and side effect profile constraints.

---

How Do R&D Trends Affect Future Market Trajectories?

Amoxicillin:
No significant new R&D investments due to widespread generic availability. Focus shifts to addressing resistance through combination therapies or modified formulations.

Omeprazole Magnesium:
Ongoing research into improved formulations, combination therapies, and alternative PPIs. No substantial pipeline innovations are expected, but incremental improvements ensure sustained sales.

Rifabutin:
Limited R&D activity. Focus remains on optimizing existing formulations for better efficacy and safety profiles, particularly for TB treatment regimens in high-burden regions.

---

What Are Regulatory and Policy Influences?

• Amoxicillin:
  Generic manufacturing faces minimal regulatory barriers; however, antimicrobial stewardship policies aim to curb overprescription, affecting volume sales.

• Omeprazole Magnesium:
  Patent expirations facilitated generics; regulatory agencies focus on safety monitoring and labeling. Some jurisdictions implement stepped approaches to PPI prescribing.

• Rifabutin:
  Regulatory approval mainly limited to specific indications like TB and MAC infections. Market entry for new formulations faces hurdles due to rigorous clinical trial requirements.

---

How Will Geographic Factors Shape Market Growth?

Amoxicillin:
Developing countries exhibit high growth potential due to expanding healthcare access and infectious disease burdens. Market saturation in developed regions constrains growth.

Omeprazole Magnesium:
High adoption rates across North America, Europe, and Asia-Pacific. Emerging markets show increasing penetration due to urbanization and lifestyle changes.

Rifabutin:
Market confined mainly to regions with substantial TB burdens, such as Africa, Southeast Asia, and Latin America. HIV/AIDS treatment programs are pivotal.

---

Summary of Financial Trajectory Estimates

Drug	2023 Market Value	2030 Projection	CAGR	Main Growth Factors
Amoxicillin	$4 billion	~$4.85 billion	3.5%	Established generic, high infection rates
Omeprazole Magnesium	$4.5 billion	~$6.1 billion	4%	GERD prevalence, biosimilars, market expansion
Rifabutin	$300 million	~$370 million	2%	TB and MAC prevalence in developing markets

---

Key Takeaways

• Market growth for amoxicillin relies on infection treatment demand; no new R&D investments, dominant generic market.
• Omeprazole magnesium maintains a steady growth rate driven by GERD prevalence; biosimilar competition pressures margins.
• Rifabutin remains a niche with slow growth, primarily supported by long-standing use in TB and MAC treatment.
• Patent expiries have shifted revenue to generics, diminishing original manufacturer sales but expanding global access.
• Policy measures can influence prescribing patterns and market size, especially regarding antimicrobial stewardship and overuse mitigation.

---

FAQs

1. What factors could impair the growth of these drugs?
Emerging resistance, side effect concerns, regulatory changes, or shifts toward alternative therapies can reduce demand or slow market expansion.

2. Are there ongoing R&D efforts to develop new versions of these drugs?
Limited R&D targets Amoxicillin, focusing on resistance; Omeprazole derivatives for efficacy and safety; Rifabutin research is minimal due to niche application.

3. How does antimicrobial resistance impact Amoxicillin's market?
Rising resistance reduces clinical efficacy, prompting shifts toward combination therapies or newer antibiotics, which may alter market dynamics.

4. Will biosimilars significantly lower the market value of Omeprazole Magnesium?
Biosimilar entries have already pushed prices down; further entry could erode profit margins but could also widen access.

5. How are global health policies affecting Rifabutin?
Strengthening TB control programs in developing countries support steady demand; however, introduction of alternative therapies could influence its usage.

---

References

[1] MarketWatch, "Amoxicillin Market Size, Share & Trends," 2023
[2] ResearchAndMarkets, "Proton Pump Inhibitors Market Analysis," 2022
[3] GlobalData, "Rifabutin Market Forecast," 2022